David H. Ilson, MD, PhD

David H. Ilson, MD, PhD, discusses the utility of zolbetuximab in claudin-positive gastric cancers.

David H. Ilson, MD, PhD, discusses TKI combinations under investigation in gastric cancer.

David H. Ilson, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the use of chemotherapy in advanced gastric cancer.

David H. Ilson, MD, PhD, discusses remaining challenges with immunotherapy in gastric cancer.

David H. Ilson, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a trial from Germany comparing standard perioperative ECF/ECX chemotherapy with a regimen combining 5-FU (5-fluorouracil) with oxaliplatin and docetaxel.

David H. Ilson, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the conclusions of the RTOG 0436 trial, a phase III trial of cisplatin, paclitaxel, and radiation with or without cetuximab in the non-operative treatment of esophageal cancer.